Skip to main content

Caliper Technologies, Pharmacopeia Added to Nasdaq Biotech Index

NEW YORK, May 14 – Caliper Technologies and Pharmacopeia will be among seven new companies included in the Nasdaq Biotechnology Index as of marketing opening May 21, Nasdaq announced on Monday. 

Companies included in the Index are evaluated semi-annually for minimum price, market value, and average daily share volume requirements.

Sixteen companies will be removed, including Lexicon Genetics. The Woodlands, Texas-based company on May 8 announced flat revenues first-quarter 2001 compared to the year-ago quarter.

Caliper, based in Mountain View, Calif., designs and manufactures lab-on-chip technologies. It had a market capitalization of $385 million at the time of selection.

Pharmacopeia of Princeton, NJ, has a drug discovery segment and recently merged its four software units into a single subsidiary called Accelrys. The company had a market capitalization of $23 million at the time of its selection.

The Nasdaq Biotechnology Index, which was started in 1993, increased 23 percent in 2000.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.